Research progress on the mechanism of annexin A family members in breast cancer

doi:10.16352/j.issn.1001-6325.2024.03.0393

Abstract

Abstract: The annexins(ANX) family is widely present in the cell membrane, cytoplasm or extracellular matrix. As key tumor regulatory molecules, annexins A (ANX A) family can promote or inhibit invasion and metastasis of breast cancer cells by influencing cell membrane and cytoskeleton formation and participating in signaling pathways. ANX A family also plays a role in the apoptosis of breast cancer cells by regulation of pro-apoptotic proteins and cell cycle independent kinases (CDKs) and related pathways. In addition, ANX A family can also promote therapeutic resistance to a large number of drugs. For instance,ANX A1 enhances triple-negative breast cancer resistance by inducing epithelial-mesenchymal transformation. ANX A4 induces resistance by forming ANX A4-Fhit complexes and secretion of exosomes containing ANX A6 promotes paclitaxel resistance in breast cancer cells in a YAP1-dependent manner. So ANX A family may be a new target for breast cancer treatment.

Key words: annexins A family, breast cancer, tumorigenesis

CLC Number:

NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan. Research progress on the mechanism of annexin A family members in breast cancer[J]. Basic & Clinical Medicine, 2024, 44(3): 393-397.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2024.03.0393

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2024/V44/I3/393

References 25

[1]	Li N, Xi Y, Du H, et al. Annexin A4 is dispensable for hair cell development and function[J]. Front Cell Dev Biol, 2021, 9: 680155. doi:10.3389/fcell.2021.680155.
[2]	Hu Z, Li L, Zhu B, et al. Annexin A5 is essential for PKCθtranslocation during T-cell activation[J]. J Biol Chem, 2020, 295: 14214-14221.
[3]	Yu ZZ, Liu YY, Zhu W, et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers[J].J Immunother Cancer,2023,11:e006345. doi:10.1136/jitc-2022-006345.
[4]	Głowacka A, Bieganowski P, Jurewicz E, et al. Regula-tion of S100A10 gene expression[J]. Biomolecules,2021,11:974.doi:10.3390/biom11070974.
[5]	Liu J, Wang H, Zheng M, et al. p53 and ANXA4/NF-κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma[J].Int J Mol Med, 2020,46:2102-2114.
[6]	Scala MC, Di Micco S, Lanzillotta D, et al. Overcome chemoresistance: biophysical and structural analysis of synthetic Fhit-derived peptides[J]. Front Mol Biosci, 2021,8:715263. doi:10.3389/fmolb.2021.715263.
[7]	Guo Z, Guo A, Zhou C. Breast cancer stem cell-derived ANXA6-containing exosomes sustain paclitaxel resistance and cancer aggressiveness in breast cancer[J]. Front Cell Dev Biol, 2021, 9: 718721. doi:10.3389/fcell.2021.718721.
[8]	Song L, Li H, Ma RR, et al. E2F1-initiated transcription of PRSS22 promotes breast cancer metastasis by cleaving ANXA1 and activating FPR2/ERK signaling pathway[J]. Cell Death Dis, 2022, 13: 982. doi:10.1038/s41419-022-05414-3.
[9]	Tang L, Chen Y, Chen H, et al. DCST1-AS1 promotes TGF-β-induced epithelial-mesenchymal transition and enhances chemoresistance in triple-negative breast cancer Cells via ANXA1[J]. Front Oncol, 2020, 10: 280. doi:10.3389/fonc.2020.00280.
[10]	Long Y, Chong T, Lyu X, et al. FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer[J].J Exp Clin Cancer Res,2022,41:301.doi:10.1186/s13046-022-02504-0.
[11]	Fan Y, Si W, Ji W, et al. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells[J]. Breast Cancer Res, 2019, 21: 66. doi:10.1186/s13058-019-1147-7.
[12]	Strand E, Hollås H, Sakya SA, et al. Annexin A2 binds the internal ribosomal entry site of c-myc mRNA and regulates its translation[J]. RNA Biol, 2021,18: 337-354.
[13]	Du R, Liu B, Zhou L, et al. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer[J]. Cell Death Dis,2018, 9: 126. doi:10.1038/s41419-017-0143-z.
[14]	Kim JY, Jung EJ, Park HJ, et al. Tumor-suppressing effect of silencing of annexin A3 expression in breast cancer[J]. Clin Breast Cancer, 2018, 18: e713-e719.
[15]	Kim JY, Jung EJ, Kim JM, et al. miR-221 and miR-222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3[J].Exp Ther Med,2023,25:127. doi:10.3892/etm.2023.11826.
[16]	Li L, Zhang R, Liu Y, et al. ANXA4 activates JAK-STAT3 signaling by interacting with ANXA1 in basal-Like breast cancer[J].DNA Cell Biol, 2020, 39: 1649-1656.
[17]	Hein T, Krammer PH, Weyd H. Molecular analysis of Annexin expression in cancer[J]. BMC cancer, 2022, 22: 994. doi:10.1186/s12885-022-10075-8.
[18]	Kang TH, Park JH, Yang A, et al. Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment[J].Nat Commun,2020,11:1137. doi:10.1038/s41467-020-14821-z.
[19]	Hoque M, Elmaghrabi YA, Köse M, et al. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells[J]. FEBS J, 2020, 287: 2961-2978.
[20]	Sakwe AM, Koumangoye R, Guillory B, et al. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions[J]. Exp Cell Res, 2011, 317: 823-837.
[21]	Li T, Tao Z, Zhu Y, et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer[J]. Cell Death Dis, 2021, 12: 684.doi:10.1038/s41419-021-03963-7.
[22]	Williams SD, Smith TM, Stewart LV, et al. Hypoxia-inducible expression of annexin A6 enhances the resistance of triple-negative breast cancer cells to EGFR and AR antagonists[J]. Cells, 2022, 11: 3007.doi:10.3390/cells11193007.
[23]	Rossetti S, Sacchi N. 3D mammary epithelial cell models: a goldmine of DCIS biomarkers and morphogene-tic mechanisms[J]. Cancers, 2019, 11: 130. doi:10.3390/cancers11020130.
[24]	田焕娜,吴雪艳,王小杰.敲低膜联蛋白A7对乳腺癌MCF-7细胞凋亡的影响[J]. 承德医学院学报, 2015: 193-195.
[25]	Wang Z, Zhou X, Deng X, et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer[J]. Front Oncol, 2023, 13: 1166666. doi:10.3389/fonc.2023.1166666.